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Abstract
Rationale: The sterilizing activity of the regimen used to treat multidrug resistant tuberculosis (MDR TB) has not been
studied in a mouse model.
Objective and Methods: Swiss mice were intravenously inoculated with 6 log10 of Mycobacterium tuberculosis (TB) strain
H37Rv, treated with second-line drug combinations with or without the diarylquinoline TMC207, and then followed without
treatment for 3 more months to determine relapse rates (modified Cornell model).
Measurements: Bactericidal efficacy was assessed by quantitative lung colony-forming unit (CFU) counts. Sterilizing efficacy
was assessed by measuring bacteriological relapse rates 3 months after the end of treatment.
Main Results: The relapse rate observed after 12 months treatment with the WHO recommended MDR TB regimen
(amikacin, ethionamide, pyrazinamide and moxifloxacin) was equivalent to the relapse rate observed after 6 months
treatment with the recommended drug susceptible TB regimen (rifampin, isoniazid and pyrazinamide). When TMC207 was
added to this MDR TB regimen, the treatment duration needed to reach the same relapse rate dropped to 6 months. A
similar relapse rate was also obtained with a 6-month completely oral regimen including TMC207, moxifloxacin and
pyrazinamide but excluding both amikacin and ethionamide.
Conclusions: In this murine model the duration of the WHO MDR TB treatment could be reduced to 12 months instead of
the recommended 18–24 months. The inclusion of TMC207 in the WHO MDR TB treatment regimen has the potential to
further shorten the treatment duration and at the same time to simplify treatment by eliminating the need to include an
injectable aminoglycoside.
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Introduction
As the leading cause of death from curable infectious diseases
worldwide, tuberculosis (TB) is a serious global health issue [1].
The high rates of TB incidence and prevalence in developing
countries have a considerable impact on population-level morbid-
ity and mortality, particularly in settings where HIV incidence
rates are high [2]. Inappropriate administration of essential anti-
TB drugs leads to the emergence of resistant bacilli, thereby
creating an additional obstacle to TB control [3]. In 2004, the
World Health Organization (WHO) reported more than 400,000
new cases of multi-drug resistant TB (MDR-TB), defined as being
resistant to isoniazid and rifampin [4]. The WHO recommended
regimen to treat MDR TB includes an injectable aminoglycoside,
a fluoroquinolone, pyrazinamide and/or ethambutol if the strain is
susceptible in addition to one or two less active second-line drugs
(ethionamide, linezolid, PAS, cycloserine…). The recommended
duration of treatment with this regimen is at least 18 months after
sputum culture conversion and extended to 24 months in patients
with extensive pulmonary damage [5]. The recommended
duration of treatment for MDR TB patients has not been
adequately studied in controlled clinical trials.
TMC207 (R207910) is a diarylquinoline with a new mechanism
of action (inhibition of ATP synthase), and is in clinical
development for treatment of both drug susceptible (DS) and
MDR TB. Its minimal inhibitory concentration (MIC) against
Mycobacterium tuberculosis (M.tb) is very low (0.06 mg/ml). In mice
intravenously (IV) inoculated with M.tb, TMC207 combined with
first-line anti-TB drugs shortened the treatment duration from 6 to
4 months [6]. In MDR TB patients, it increased the proportion of
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sputum culture conversion from 9 to 48% after 2 months of
treatment [7]. The optimal second-line background regimen to
combine with TMC207 and the duration of treatment with such
regimen are not known. We conducted a study to determine the
sterilizing efficacy and optimal duration of treatment of the WHO
recommended MDR TB regimen with and without addition of
TMC207. Part of the results presented here have been presented
at the 48th ICAAC in Washington [8].
Materials and Methods
The laboratory has been approved on July 27th, 2004 to carry
out animal experiments. Nicolas Veziris who carried the animal
experiments has the following license number: 75-1531. We
followed the animal experiment guidelines of the Faculte´ de
Me´decine Pierre-et-Marie Curie.
Antimicrobial Agents
TMC207 was provided by Johnson & Johnson (Beerse,
Belgium), while the other compounds were purchased from the
following manufactures: isoniazid (H) from Laphal (Allauch,
France), rifampin (R), pyrazinamide (Z) from Aventis (Antony,
France), moxifloxacin (M) from Bayer (Puteaux, France), amikacin
from Bristol-Myers Squibb (La De´fense, France), and ethionamide
from Sigma (France).
Mycobacterium tuberculosis strain
The H37Rv strain of M.tb was grown on Lo¨wenstein-Jensen
medium (LJ slants). Colonies were subcultured in Dubos broth
(Becton, Dickinson and company, Le Pont de Claix, France) for
7 days at 37uC. The turbidity of resulting suspension was
adjusted with normal saline to match that of standard 1 mg/ml
suspension of Mycobacterium bovis BCG and was further diluted
with normal saline to obtain a 0.2 mg/ml suspension for mouse
inoculation.
Infection of the mice
Four hundred seventy female four-week-old Swiss mice were
purchased from the Janvier Breeding Center (Le Genest Saint-Isle,
France). They were intravenously infected in the tail vein with
0.5 ml of bacterial suspension containing approximately 1.16106
colony forming units (CFU) of M.tb H37Rv.
Chemotherapy
Mice were randomized into ten groups (table 1). Negative
control group 1 consisted of 40 infected and untreated mice, of
which 10 were killed the day after infection (D-18), 20 at beginning
of treatment (D0), and 10 kept untreated for assessing mortality
from tuberculosis. Group 2 was a positive control group with 40
mice receiving the standard WHO regimen for DS TB i.e. 2
months of rifampin (R) isoniazid (H) and pyrazinamide (Z)
followed by 4 months of R and H (abbreviated as 2RHZ/4RH). In
group 3, 30 mice received the most active TMC207 containing
regimen described to date i.e. R, TMC 207 (J) and Z for 2 months
followed by 2 months of J and R (2JRZ/2JR) [6]. In group 4, 90
mice received the WHO recommended MDR TB regimen: 2
months of amikacin (A), ethionamide (Et), moxifloxacin (M) and Z
followed by EtM for 4, 7 or 10 months (2AEtMZ/4EtM,
2AEtMZ/7EtM, 2AEtMZ/10EtM). In group 5, 90 mice received
JZM for 2 months followed by JM for 2, 4 or 7 months (2JZM/
2JM, 2JZM/4JM, 2JZM/7JM). Group 6 contained 30 mice which
were treated with the WHO MDR TB regimen to which J was
added (2 JAEtMZ/4JEtM). Groups 7 and 8 contained 30 mice
each receiving the MDR TB regimen for 6 months with J
substituting for either M or Z (2JAEtZ/4JEt and 2JAEtM/4JEtM).
Groups 9 and 10 contained 30 mice each, treated with either JM
or JZ for 6 months (6JM and 6JZ).
Treatment began 19 days after intravenous infection (D0) i.e
when a large bacterial population had developed. All groups were
treated 5 days per week. Drug suspensions were prepared weekly
Table 1. Experiment Design.
Regimen D-18 D0 4 mo 6 mo 7 mo 9 mo 12 mo 15 mo Total
1 Untreated 10 20 10* 40
2 2RHZ+4RH 10 30 40
3 2JRZ+2JR 10 20 30
4 2AEtMZ+4EtM 10 20 30
2AEtMZ+7EtM 10 20 30
2AEtMZ+10EtM 10 20 30
5 2JZM+2JM 10 20 30
2JZM+4JM 10 20 30
2JZM+7JM 10 20 30
6 2JAEtMZ+4JEtM 10 20 30
7 2JAEtZ+4JEt 10 20 30
8 2JAEtM+4JEtM 10 20 30
9 6JM 10 20 30
10 6JZ 10 20 30
Total 10 20 20 100 40 210 50 20 440
Definition of abbreviations: J = TMC 207, R = Rifampin, M=Moxifloxacin, H = Isoniazid, Z = Pyrazinamide, A = amikacin, Et = ethionamide.
Mice were infected intravenously with 1.16106 of M. tuberculosis H37Rv.
Day -18: the day after infection, Day 0: start of treatment.
*Mice kept untreated for mortality assessment.
All drugs were given 5 times per week at the following doses: J, 25 mg/kg; R, 10 mg/kg; M, 100 mg/kg; H, 25 mg/kg; Z, 150 mg/kg; A, 150 mg/kg; Et, 50 mg/kg.
doi:10.1371/journal.pone.0017556.t001
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and kept at 4uC except for TMC207 which was prepared monthly
in 20% hydroxypropyl-B-cyclodextrin and kept at 4uC. Amikacin
was given by subcutaneous injection at 150 mg/kg as previously
described [9]. All the other drugs were given by gavage at the
following doses: J 25 mg/kg, R 10 mg/kg, Z 150 mg/kg, M
100 mg/kg (once-a day), H 25 mg/kg and Et 50 mg/kg. R was
administered one hour before other drugs to avoid drug-drug
interactions [10,11,12]. Drug doses were selected to provide areas
under the curve (AUC) values in mice comparable with those
achievable in human [9,11,12,13]. For consistency, 4 weeks of
treatment was considered as corresponding to one month [11].
Assessment of infection and treatment efficacy
To assess the extent of M.tb infection and to provide baseline
values before initiation of chemotherapy, 10 untreated control
mice were sacrificed at day 1 and 20 at day 19 after infection
respectively (i.e. day 218 and day 0 in relation to the initiation of
treatment). Treated mice were sacrificed either at the end of
treatment to assess the bactericidal activity or 3 months after the
end of treatment to assess the relapse rate (sterilizing activity)
(Table 1).
The severity of infection and the effectiveness of the treatments
were assessed by survival rate, spleen weight, gross lung lesions (0:
no lesion, +: less than 10 tubercles, ++: more than 10 tubercles)
and lung CFU counts.
The number of CFU in the lungs was determined by plating
homogenized lung suspensions in triplicate on Lowenstein-Jensen
(LJ) slants, either diluted for untreated control mice or undiluted
for treated mice. In the latter case the whole suspension (3.5 ml)
was plated on 15 LJ slants. The CFU count was assessed after 6
weeks of incubation at 37uC [14].
Statistical analysis
Mean spleen weights were compared using the Student’s t test.
Proportion of positive mice 3 months after the end of treatment
were compared using the Fisher’s exact test (FET) to compare
relapse rates since samples were small (less than 30 mice).
Results
Survival rate
Fify-two out of 440 mice died during the 15 months experiment.
All of the 10 untreated mice died between 18 and 94 days after
infection. Deaths among treated mice during the first month were
assumed to be due to tuberculosis as mice appeared to be severely
ill and had continuous weight loss after becoming infected whereas
death occurring after the first month were due to gavage or
injection accidents (such mice had all gained weight and
splenomegaly had decreased). In group 2, 2 mice out of 39 died
because of gavage accidents after the first month, in group 3, 2
mice out of 30 died (1 during first month and 1 afterwards), in
group 4, 18 mice out of 90 died (6 during the first month and 11
because of gavage or injection accident afterwards), in group 5, 6
mice out of 90 died (5 during first month and one because of a
gavage accident), in group 6, 4 mice out of 30 died (3 during first
month and one because of gavage or injection accident), in group
7, no mice died, in group 8, 2 mice out of 30 died in the first
month, in group 9, 3 mice died (2 during first month and one
because of gavage accident) and in group 10, 6 mice out of 30 died
(2 during the first month and 4 afterwards).
Spleen weight
The day after infection (D-18), the mean spleen weight was
115630 mg, while 18 days later, at the start of treatment (D0), the
mean spleen weight had increased to reach 6086144 mg. During
treatment, mean spleen weights decreased significantly in all the
groups (p,0.005), compared to the mean spleen weight on D0
(results not shown).
Gross lung lesions
The number of gross lung lesions increased from 0 the day after
inoculation to ++18 days later at the start of treatment. After three
and four months of treatment, the number of lesions decreased
progressively. There was no difference in gross lung lesions among
treated groups (results not shown).
Enumeration of CFU in the lungs at the end of treatment
The day after infection, the mean lung CFU count was 5.6
log10. On D0, the mean lung CFU had increased to 7.1 log 10.
All mice were culture negative at the end of treatment in all
treatment groups except 1 mouse in the JZM group after 4 months
(3 colonies), 1 mouse in the AEtMZ group after 9 month (2
colonies) and 1 mouse in the AEtMZ group after 12 months (1
colony).
Relapses after treatment completion
The proportion of mice that relapsed (i.e. became culture
positive) 3 months after the end of treatment was determined for
each combination (Table 2).
In the group receiving 2 months of RHZ followed by 4 months
of RH, 3 out of 28 mice (11%) relapsed with a mean 1.8 log CFU.
In the group receiving 2 months of JRZ followed by 2 months of
JR, 3 out of 19 mice (16%) relapsed with a mean 2.5 log10 CFU.
Among mice treated with the MDR WHO regimen, i.e. 2 months
of AEtMZ followed by 4, 7 or 10 months of EtM, the relapse rates
were 11/19 (58%) with a mean 2.4 log10 CFU, 8/16 (50%) with a
mean 2.0 log10 CFU and 4/18 (22%) with a mean 0.9 log10 CFU.
In the group receiving 2 months of JZM followed by 2, 4 or 7
months of JM, relapse rates were 8/20 (40%) with a mean 1.7
log10 CFU, 2/19 (11%) with a mean 0.3 log10 CFU and 5/20
Table 2. Proportion of mice with positive culture of lung 3
months after treatment completion (relapse).*
Regimen 4 mo 6 mo 9 mo 12 mo
2RHZ+4RH 3/28 (11%)
2JRZ+2JR 3/19 (16%)
2AEtMZ+4EtM 11/19 (58%)a
2AEtMZ+7EtM 8/16 (50%)a
2AEtMZ+10EtM 4/18 (22%)b
2JZM+2JM 8/20 (40%)a
2JZM+4JM 2/19 (11%)b
2JZM+7JM 5/20 (25%)b
2JAEtMZ+4JEtM 5/18 (28%)b
2JAEtZ+4JEt 9/20 (45%)a
2JAEtM+4JEtM 10/20 (50%)a
6JM 9/20 (45%)
6JZ 4/18 (22%)
*Lung CFU count at start of treatment (D0): 7.1 log10 CFU.
Definition of abbreviations: J = TMC 207, R = Rifampin, M=Moxifloxacin,
H = Isoniazid, Z = Pyrazinamide, A = amikacin, Et = ethionamide.
asignificantly more relapses than RHZ (p,0.05).
bnot significantly different from RHZ (p.0.05).
doi:10.1371/journal.pone.0017556.t002
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(25%) with a mean 2.2 log10 CFU. Five out of 18 mice (28%) that
received WHO MDR regimen combined with J, i.e. 2 months of
JAEtMZ followed by 4 months of JEtM, relapsed with a mean 1.5
log10 CFU. Nine out of 20 mice (45%) that received the WHO
MDR regimen in which J replaced M, i.e. 2 months of JAEtZ
followed by 4 months of JEt, relapsed with a mean 2.3 log10 CFU.
Ten out of 20 mice (50%) that received the WHO MDR regimen
in which J replaced Z, i.e. 2 months of JAEtM followed by 4
months of JEtM, relapsed with a mean 1.8 log10 CFU. And
finally, nine out of 20 mice (45%) that received the 6 months JM
combination relapsed with a mean 1.8 log10 CFU and four out of
18 mice (22%) that received the 6 months JZ combination relapsed
with a mean 0.9 log10 CFU.
Compared to the standard WHO DS regimen (group 2), the
relapse rate of the WHO MDR regimen (AEtMZ, group 3) was
significantly worse after 6 and 9 months (p = 0.0009 and 0.009
respectively) but not after 12 months (p = 1). When J was added to
the WHO MDR regimen (group 6) the relapse after 6 months
became equivalent to that of RHZ (p= 0.23). When M or Z were
removed (groups 7 and 8) from this regimen the relapse rate
increased again and became significantly worse compared to that
of RHZ (p= 0.02 and 0.004, respectively).
Compared to the standard WHO regimen for DS TB (RHZ,
group 2), the relapse rate of regimen JZM was significantly worse
after 4 months (p = 0.03) but was equivalent after 6 and 9 months
(p = 1 and 0.25, respectively). Even the regimen combining only J
and Z (group 10) for 6 months achieved an acceptable relapse rate
in this experiment.
Discussion
We have previously shown that the MDR TB regimen
combining amikacin, moxifloxacin, ethionamide and pyrazin-
amide has the highest bactericidal activity in the mouse model,
resulting in culture conversion after 9 months of treatment [15].
However, in order to determine the minimal duration of
treatment, one must conduct relapse studies studying the sterilizing
activity of drug regimens [6,16,17,18]. In the present work we
studied the sterilizing activity of the WHO recommended regimen.
The relapse rate obtained after 12 months was not statistically
different from that obtained after 6 months treatment with the
WHO recommended regimen to treat DS TB.
Several factors complicate the extrapolation of mouse data to
the human situation. Firstly, the pathology of tuberculosis in mice
is different from humans, the spread of the bacilli is haematog-
enous rather than bronchogenous, tuberculosis develops much
faster than in humans (mice die in less than 2 months), and mice
do not develop lung cavities [19]. For these reasons, we included
the standard WHO treatment rifampin, isoniazid and pyrazin-
amide as a control group. Since the activity of this regimen is well
established in man as well as in the murine model, it facilitates
interpretation of the results [16].
Secondly, some dosages used here may not exactly mimic those
used in humans. E.g. the 150 mg/kg dose of amikacin generates a
Cmax in mice that is approximately four times higher than the one
obtained in patients taking a 15 mg/kg dose. On the other hand,
the intracellular penetration of aminoglycosides is known to be low
and their efficacy is therefore expected to be better in patients with
mainly extracellular TB replication compared to mice with mainly
intracellularly replication [20]. Several studies in mice have indeed
shown very limited activities of aminoglycosides, even when used
at high concentrations [21,22]. For moxifloxacin the 100 mg/kg
dosing used in mice generates an AUC equivalent to the lowest
AUC that can be achieved in patients and that is about 50% the
highest AUC that can be achieved in patients [23,24,25]. The
pyrazinamide dose is bioequivalent to that used in patients [16].
Taken together these comparisons suggest that the PK of the drugs
used in this model are not far from the human PK at the usual
dosing of these drugs. For ethionamide there are no mouse PK
data allowing a comparison.
The third limitation is the statistical power of the study. To
achieve a power of 80% to detect superiority between regimens,
mouse relapse studies with 20 animals per group require an
absolute difference of 40% in relapse rates between regimens
[26,27]. To achieve a power of 80% to demonstrate non-
inferiority with an acceptable non-inferiority margin, the numbers
of mice required in each group are much higher than those used in
the current study. This means that two groups can have same
relapse rate due to same activity or due to the fact that the
difference of activity is too small to be revealed by the small
number of animals. Consequently a lack of difference should be
interpreted very carefully. Despite of this statistical limitation, it
has been shown previously that the duration of DS TB treatment
assessed in mouse relapse studies can be predictive for the duration
of TB treatment in human [16]. The reproducibility and
generalizability of this prediction will become clearer as more
new TB regimens, now being tested in different mouse models, will
be tested in clinical trials in the coming years.
The last limitation is that MDR TB isolates are by definition
resistant to isoniazid and rifampin, but usually have also acquired
additional resistance mutations. In this context, the impact of
resistance to pyrazinamide on minimal treatment durations may
be a very important one. Acquired pyrazinamide resistance is very
common in MDR TB patients, and the data summarized in table 2
demonstrate that exclusion of pyrazinamide from a regimen leads
to higher relapse rates (2JMZ+4JM 11% vs 6JM 45% p=0.03 and
2JAEtMZ+4JEtM 28% vs 2JAEtM+4JEtM 50% p=0.32).
Similarly, resistance against fluoroquinolones is common in
MDR TB patients and although our data do not suggest that
such resistance would lead to higher relapse rates (2JMZ+4JM
11% vs 6JZ 22% p=0.4 and 2JAEtMZ+4JEtM 28% vs
2JAEtZ+4JEtZ 45% p=0.32), the addition of a third active drug
to the combination of TMC207 and pyrazinamide is very
important to prevent development of further resistance mutations.
Our data should therefore not be seen as a rationale to shorten the
recommended treatment duration for MDR TB patients.
However this murine study supports the design of clinical trials
assessing reduced treatment durations. A recent observational
study by Van Deun and colleagues suggests that the duration of
treatment for selected MDR TB patients can be reduced to 9
months using a clofazimine-based regimen [28]. Taken together
the results of these two studies support the design of clinical trials
evaluating the reduction of the treatment duration of the MDR-
TB WHO recommended regimen from 18–24 to 12 months, if
sensitivity to both moxifloxacin and pyrazinamide can be
established [5].
The second aim of this study was to assess the contribution of
the diarylquinoline TMC207 to the sterilizing activity of MDR
regimens. TMC207 has been shown to improve both the
bactericidal and the sterilizing activity of the first line regimen
RHZ [6,29]. The combination of TMC207 with the second-line
MDR regimen (JAEtMZ) also resulted in acceleration of the
bactericidal activity in a 2 months experiment [9]. In the present
study the addition of TMC207 to the WHO MDR regimen
(AEtMZ) shortened the time to achieve a relapse rate equivalent to
that of RHZ from 12 to 6 months. Interestingly when amikacin
and ethionamide were excluded from this combination, the relapse
rate did not increase: the group receiving JZM for 6 months also
TMC 207 and Second-Line Antituberculous Regimen
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achieved a relapse rate equivalent to that of RHZ after 6 months.
This result is important since amikacin and ethionamide are not
well tolerated in humans [30,31] and it raises the possibility to use
a completely oral regimen to treat MDR TB in a shorter time
frame. Even the double combination of TMC207 and Z had
surprisingly good sterilizing activity after just 6 months of
treatment. As discussed above, double combinations of TB drugs
are not warranted because of the risk of emergence of resistance.
The slight increase in relapse rate obtained by extending
treatment with JM from 6 to 9 months (groups 5B and 5C) is
puzzling. Such increase could be due to the fact that too few mice
were studied per group (as discussed above in the limitations of the
study), to the development of resistance, or to the possibility that
the combination of TMC207+M is not active against bacilli
persisting after 6 months of treatment. The emergence of
resistance was excluded by testing the sensitivity of strains isolated
after 9 months. The combination of TMC207+M might indeed
not be sufficient to kill all persistent bacilli, but is very efficient if Z
is added, and not stopped after 2 months. Indeed, it was recently
reported that the regimen JZM resulted in acceptable relapse rates
after just 5 months, and complete bacteriological cure (0%
relapses) after 6 months of treatment [32]. These data suggest that
pyrazinamide treatment is still efficacious after 2 months of
treatment and suggests that the observed bactericidal synergy with
J [33] is extended in the sterilizing phase.
The control group receiving the DS TB regimen JRZ achieved
a relapse rate equivalent to that of the 6 months standard WHO
regimen RHZ after 4 months. This confirms an earlier study [6]
and suggests that substitution of isoniazid by TMC207 could
shorten the treatment duration of DS TB to 4 months. A recent
study also showed that substitution of isoniazid by TMC207 and
rifampin by rifapentin led to an acceptable relapse rate after 3
months treatment [32].
In conclusion, we showed that treatment of mice with a
moxifloxacin+pyrazinamide based regimen, as recommended by
WHO for the treatment of MDR TB, results in stable cure in 12
months. An entirely oral regimen combining TMC207, moxi-
floxacin and pyrazinamide could reduce the duration needed to
produce stable cure to only 6 months. These treatment duration
estimates need to confirmed in clinical trials. Preliminary results of
an ongoing clinical trial with TMC207 against MDR TB are
encouraging [7,34].
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